Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.30 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22843961 | 0.93 | PTGS1 (0.32) | KDM4ECA1CA2GAAPTGS1 | |
| SCHEMBL20197866 | 0.90 | PTGS1 (0.40) | MAPK1SMN1; SMN2LMNAGAARAB9A | |
| SCHEMBL17953261 | 0.85 | PTGS1 (0.41) | KDM4EMAPK1SMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL17325350 | 0.85 | PTGS1 (0.41) | KDM4EMAPK1SMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL25148661 | 0.84 | CA1 (0.34) | MAPK1CA1CA2PDE4APDE4B | |
| SCHEMBL24864446 | 0.83 | RAB9A (0.39) | CA1CA2RAB9A | |
| SCHEMBL20147108 | 0.83 | MAPT (0.38) | KDM4ELMNAL3MBTL1 | |
| SCHEMBL19401691 | 0.81 | CA1 (0.37) | CA1CA2 | |
| SCHEMBL18402748 | 0.79 | PTGS1 (0.46) | KDM4EMAPK1SMN1; SMN2GAAPTGS1 | |
| SCHEMBL24268457 | 0.79 | CA1 (0.34) | KDM4ECA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077008-B1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (CN) | 2023-10-04 | — | — | EP | disclosed |
| EP-3834846-A1 | ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-2750681-B1 | BRANCHED DISCRETE PEG CONSTRUCTS | QUANTA BIODESIGN LTD (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20190275181-A1 | Compounds for Positron Emission Tomography | ENDOCYTE INC (US) | 2019-09-12 | — | — | US | disclosed |
| US-20170313656-A1 | Branched Discrete PEG Constructs | QUANTA BIODESIGN, LTD. | 2017-11-02 | — | — | US | disclosed |
| EP-2448930-B1 | N-((S)-2-Oxo-tetrahydro-furan-3-yl)-amide derivatives as inhibitors of the bacterial quorum sensing for treating plant or animal diseases and for preventing the formation of biofilms on medical devices | THE NAT INST FOR BIOTECHNOLOGY IN THE NEGEV LTD (IL) | 2017-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313656-A1 | Branched Discrete PEG Constructs | BTD, IDUA, DNPEP | KDM4E 3092/4885MAPK1 1302/4885SMN1; SMN2 3563/4885 |
| US-20190275181-A1 | Compounds for Positron Emission Tomography | FOLH1, FOLR2, FOLR1 | KDM4E 1706/4885MAPK1 3440/4885SMN1; SMN2 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.